pertuzumab into your bloodstream (intravenously) trastuzumab can be given intravenously or as an injection under the skin (subcutaneously) Phesgo is given as an injection under your skin; As an ...

Pertuzumab and trastuzumab block certain proteins, known as HER2, on the cancer cells. By blocking these proteins, Phesgo can cause cancer cells to die and can prevent cancer cells from growing or ...

The FDA recommendations for pertuzumab, trastuzumab, ... Colomer R, Stroyakovskii D, Nowecki Z, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy ...

Some people have a newer drug called Phesgo ® instead of pertuzumab and trastuzumab. Phesgo ® combines pertuzumab with trastuzumab. Your nurse gives it to you as an injection under the skin over ...

Jackisch C, Im S, Mattar A, et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term ...

The combination of trastuzumab, pertuzumab, and hyaluronidase [Phesgo] for subcutaneous injection has an FDA-approved indication for both early-stage and metastatic disease. 6 It can be used in the ...

Transcript: Chau T. Dang, MD: We use IV [intravenous] trastuzumab-pertuzumab during the chemotherapy phase because the patient already has a needle inserted, and it’s easy to continue delivering IV ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...